Xanthone (Synonyms: NSC 14978, 9-oxo Xanthone, 9-Xanthone) |
| カタログ番号GC17356 |
キサントンはマンゴスチンから分離され、発がんのさまざまな段階で細胞分裂と成長、アポトーシス、炎症、転移を制御することが知られています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 90-47-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Xanthone shows the antagonism of endogenous nitric oxide synthase (NOS) inhibitors, it has antitumor, antihepatotoxic, anti-inflammatory and antimicrobial activities [1]. Two derivatives of xanthone potently inhibited nitric oxide synthesis with IC50 values of 4.3 and 4.4 μM, respectively [2].
In endothelial cells, NOS synthesizes nitric oxide (NO) from L-arginine. In the maintenance of vascular structure and tone, NO has been thought to play a key role [1].
Asymmetric dimethylarginine (ADMA) is synthesized by protein arginine methyltransferases (PRMTs), using S-adenosylmethionine as methyl group donor. Dimethylarginine dimethylaminohydrolase (DDAH) degrades ADMA to L-citrulline and dimethylamine. There are two different isoforms of DDAH, DDAH-1 and DDAH-2. Typically, DDAH-1 is found in tissues containing neuronal NOS, whereas DDAH-2 predominates in tissues expressing the endothelial isoform of NOS. In cultured endothelial cells, xanthones showed the inhibition of the upregulation of MCP-1 expression, the enhancement of monocytes adhesion and the increase in the release of LDH, concomitantly with the reduction of ADMA levels. These results suggest that xanthones protect against high-lipid-level-induced endothelial damage. This protective effect of xanthones is related to the reduction of ADMA concentration [1].
A single injection of native LDL caused a rapid accumulation and oxidation of LDL in the arterial wall. At 6 to 12 h after injection of LDL, ICAM-1 expression increased and led to endothelial dysfunction and an elevation of ADMA level. In vivo, pretreatment with xanthones attenuated the effect of the injection of LDL [1].
References:
[1]. Jiang DJ, Dai Z and Li YJ. Pharmacological effects of xanthones as cardiovascular protective agents. Cardiovasc Drug Rev, 2004, 22(2):91-102.
[2]. Boonnak N, Khamthip A, Karalai C, et al. Nitric Oxide Inhibitory Activity of Xanthones from the Green Fruits of Cratoxylum formosum ssp. pruniflorum. Australian Journal of Chemistry, 2010, 63(11):1550-1556.
| Cas No. | 90-47-1 | SDF | |
| 同義語 | NSC 14978, 9-oxo Xanthone, 9-Xanthone | ||
| Chemical Name | 9H-xanthen-9-one | ||
| Canonical SMILES | O=C1C2=CC=CC=C2OC3=CC=CC=C31 | ||
| Formula | C13H8O2 | M.Wt | 196.2 |
| 溶解度 | DMSO : 10 mg/mL (50.97 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0968 mL | 25.4842 mL | 50.9684 mL |
| 5 mM | 1.0194 mL | 5.0968 mL | 10.1937 mL |
| 10 mM | 0.5097 mL | 2.5484 mL | 5.0968 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *